Clinical Trial Update: 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating 5-fluorouracil/leucovorin, irinotecan, temozolomide, and bevacizumab in MGMT-silenced, microsatellite-stable metastatic colorectal …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• Temodar (Temozolomide)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Metastatic Colorectal Cancer | Phase 1, Phase 2 | Status: RECRUITING